STING1 and neoplasm: While this short-lived response could be detrimental to checkpoint inhibitor synergy, it also suggests a highly tunable effect that could be modulated by small doses specifically used to induce and maintain type I inflammatory signaling in tumors where we see anti-tumor immune responses from STING activation.